Ocumension to develop, commercialize Dexycu in greater China region

EyePoint Pharmaceuticals and Ocumension Therapeutics have signed an exclusive license agreement for the development and commercialization of Dexycu in mainland China, Hong Kong, Macau and Taiwan, according to a press release.

Dexycu (dexamethasone intraocular suspension 9%) is used to treat postoperative inflammation after ocular surgery. EyePoint will receive an upfront payment of $2 million and royalties on Dexycu sales, with future milestone payments possibly totaling up to $12 million, while Ocumension will receive the right to develop and commercialize Dexycu in these areas.

“Dexycu is an important addition to our growing portfolio of ocular disease treatments for patients in the greater China region and continues our strong partnership with EyePoint,” Ye Liu, CEO of Ocumension, said in the release. “Dexycu has the potential to become the new standard of care as a single-dose, sustained-release therapeutic option that provides long-lasting benefit for up to 22 days.”

EyePoint markets Dexycu in the United States and will maintain worldwide development and commercialization rights outside of the Ocumension-licensed territories.

EyePoint Pharmaceuticals and Ocumension Therapeutics have signed an exclusive license agreement for the development and commercialization of Dexycu in mainland China, Hong Kong, Macau and Taiwan, according to a press release.

Dexycu (dexamethasone intraocular suspension 9%) is used to treat postoperative inflammation after ocular surgery. EyePoint will receive an upfront payment of $2 million and royalties on Dexycu sales, with future milestone payments possibly totaling up to $12 million, while Ocumension will receive the right to develop and commercialize Dexycu in these areas.

“Dexycu is an important addition to our growing portfolio of ocular disease treatments for patients in the greater China region and continues our strong partnership with EyePoint,” Ye Liu, CEO of Ocumension, said in the release. “Dexycu has the potential to become the new standard of care as a single-dose, sustained-release therapeutic option that provides long-lasting benefit for up to 22 days.”

EyePoint markets Dexycu in the United States and will maintain worldwide development and commercialization rights outside of the Ocumension-licensed territories.